Regeneron Reports Second Quarter 2013 Financial and Operating Results

TARRYTOWN, N.Y.,Aug. 6, 2013/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)today announced financial and operating results for the second quarter of 2013 and provided an update on development programs.

The Company reported total revenues of$458 millionin the second quarter and$897 millionin the first half of 2013, compared to$304 millionin the second quarter and$536 millionin the first half of 2012.  EYLEA U.S. net product sales grew 70% to$330 millionin the second quarter of 2013 from$194 millionin the second quarter of 2012.  First half of 2013 EYLEA U.S. net product sales grew 103% to$644 millionfrom$318 millionin the first half of 2012.

The Company reported non-GAAP net income of$198 million, or$1.73per diluted share, in the second quarter and$398 million, or$3.50per diluted share, in the first half of 2013, compared to$102 million, or$0.90per diluted share, in the second quarter and$142 million, or$1.28per diluted share, in the first half of 2012.  Non-GAAP net income excludes non-cash share-based compensation expense, non-cash interest expense related to the Company's convertible senior notes, and non-cash income taxes.  The Company reported GAAP net income of$87 million, or$0.79per diluted share, in the second quarter and$186 million, or$1.69per diluted share, in the first half of 2013, compared to$77 million, or$0.70per diluted share, in the second quarter and$88 million, or$0.81per diluted share, in the first half of 2012.  The Company's revenues and net income in both the second quarter and first half of 2013 were reduced by two$10 millionup-front payments made to Sanofi to acquire full rights to antibodies to PDGF and antibodies to Ang2 in ophthalmology, as described below.

"We are pleased with the continued progress of EYLEA both in terms of commercialization and development in additional indications," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "Today, we reported positive Phase 3 data for EYLEA from the VIVID-DME and VISTA-DME trials in diabetic macular edema (DME).  Based upon discussions with the U.S. Food & Drug Administration, we now plan to submit a regulatory application for approval for EYLEA in the DME indication in the U.S. later this year, approximately one year ahead of our previous plan.  Additional Phase 3 trials for EYLEA, alirocumab and sarilumab continue to advance and we expect to report data from the VIBRANT study with EYLEA in macular edema following branch retinal vein occlusion and the ODYSSEY MONO study with alirocumab for hypercholesterolemia later this year; the ODYSSEY MONO trial will be the first Phase 3 data from this class.  We also moved two new antibodies into clinical development in this quarter."

• EYLEA is currently approved inthe United Statesfor the treatment of neovascular age-related macular degeneration (wet AMD) and macular edema following central retinal vein occlusion (CRVO).  In the second quarter of 2013, net sales were$330 million, compared to$194 millionin the second quarter of 2012.

• The Company and Bayer HealthCare collaborate on the global development and commercialization of EYLEA outsidethe United States, and share profits and losses from commercialization of EYLEA outsidethe United Statesexcept forJapan, where the Company receives a royalty on sales.  Regeneron maintains exclusive rights to EYLEA inthe United Statesand is entitled to all profits from any such sales.

• Bayer HealthCare commenced sales of EYLEA for the treatment of wet AMD in the fourth quarter of 2012 following receipt of regulatory approvals in the European Union,Japan,Australia, and other countries.  In the second quarter of 2013, Bayer HealthCare recorded net sales of EYLEA outside ofthe United Statesof$96 million, compared to$65 millionin the first quarter of 2013.  Regeneron's share of profits (including royalties on sales inJapan) for EYLEA was$34 millionin the second quarter of 2013, and after repaying$15 millionin development expenses, the Company recognized$19 millionin net profit from EYLEA sales outsidethe United Statesin the quarter.

• Launches in additional countries are anticipated to continue throughout 2013 as regulatory and pricing approvals for EYLEA for the treatment of wet AMD are achieved. InMay 2013, theUnited Kingdom'sNational Institute for Health and Care Excellence (NICE) issued a positive recommendation for EYLEA for the treatment of wet AMD.

• Applications for marketing authorization for EYLEA for the treatment of macular edema following CRVO are also pending inEurope,Japan, and other countries.  InJuly 2013, the European Committee for Medicinal Products for Human Use (CHMP) recommended approval of EYLEA to the European Medicines Agency (EMA) for the treatment of macular edema secondary to CRVO and final approval is anticipated by the end of the year.

• InJune 2013, the Company and Bayer HealthCare announced positive top-line results for EYLEA from the Phase 3 MYRROR study in myopic choroidal neovascularization (mCNV).  Data from this study will be presented at an upcoming medical conference. The first application for regulatory approval is expected to be submitted for this indication inAsiaby the end of 2013.

• Earlier today, the Company and Bayer HealthCare reported positive, top line, one-year results from the Phase 3 VIVID-DME and VISTA-DME trials in DME.  Data from these studies will be presented at upcoming medical conferences.  Applications for regulatory approvals inthe United StatesandEuropeare expected to be submitted for this indication by the end of 2013; the U.S. regulatory submission is approximately one year earlier than previously planned.

• The Company and Sanofi collaborate on the global development and commercialization of ZALTRAP, and share profits and losses from commercialization of ZALTRAP except forJapan, where the Company will receive a royalty on sales.

• ZALTRAP is currently approved in over 30 countries, includingthe United Statesand European Union.  Marketing authorization applications for ZALTRAP are currently under review by additional regulatory agencies worldwide.

• In the second quarter of 2013, Sanofi recorded worldwide net sales of ZALTRAP of$19 million, compared to$14 millionin the first quarter of 2013.

• Regeneron has twelve fully human monoclonal antibodies based on the Company'sVelocImmune®technology in clinical development, including seven in collaboration with Sanofi.

• ODYSSEY, a large, global Phase 3 program with alirocumab (REGN727), an antibody targeting PCSK9 to reduce LDL cholesterol, was initiated inJune 2012and is currently enrolling patients.  The ODYSSEY program includes eleven clinical trials evaluating the effect of alirocumab dosed every two weeks.  In addition, a trial of alirocumab dosed every four weeks (ODYSSEY CHOICE) will commence by the end of 2013.  The Company expects to report initial results from the Phase 3 ODYSSEY MONO trial by the end of 2013.  Alirocumab is being developed in collaboration with Sanofi.

• Data from a Phase 2a trial of dupilumab (REGN668) in allergic asthma were presented at the American Thoracic Society meeting in May 2013.  These data were also published in theNew England Journal of MedicineinJune 2013.  In the second quarter of 2013, Phase 2b trials of dupilumab in allergic asthma and atopic dermatitis were initiated and are currently enrolling patients.  Dupilumab is being developed in collaboration with Sanofi.

• The Phase 3 program with sarilumab (REGN88) in rheumatoid arthritis includes multiple trials.  SARIL-RA-MOBILITY has completed enrollment and data are expected in early 2014.   SARIL-RA-TARGET continues to enroll patients.  SARIL-RA-COMPARE and SARIL-RA-ASCERTAIN were initiated during the second quarter of 2013.  Additionally, a Phase 2 study, SARIL-NIU-SATURN, in non-infectious uveitis will commence in the third quarter of 2013.  Sarilumab is being developed in collaboration with Sanofi.

• Two novel antibodies against undisclosed targets, REGN1193 and REGN2009, entered clinical development.  REGN2009 is being developed in collaboration with Sanofi.  Development of REGN846, which completed a Phase 1 study against an undisclosed target, has been discontinued.

• InMay 2013, the Company made two$10 millionup-front payments to Sanofi in connection with the acquisition of full rights to antibodies targeting the PDGF (platelet derived growth factor) family of receptors and ligands in ophthalmology and all other indications and to antibodies targeting the Ang2 receptor and ligand in ophthalmology.  These antibodies were invested at Regeneron and previously included in the antibody collaboration with Sanofi.

Total Revenues:Total revenues were$458 millionin the second quarter of 2013, compared to$304 millionin the second quarter of 2012.  Total revenues include collaboration revenues of$117 millionin the second quarter of 2013, compared to$98 millionin the second quarter of 2012.  Collaboration revenues in the second quarter of 2013 were reduced by two$10 millionup-front payments made to Sanofi to acquire full rights to antibodies to PDGF and antibodies to Ang2 in opthalmology.

Product Revenues:Net product sales were$334 millionin the second quarter of 2013, compared to$200 millionin the second quarter of 2012.  EYLEA net product sales were$330 millionin the second quarter of 2013, compared to$194 millionin the second quarter of 2012.  ARCALYST net product sales were$4 millionin the second quarter of 2013, compared to$6 millionin the second quarter of 2012.

Research and Development (R&D) Expenses:GAAP R&D expenses were$187 millionin the second quarter of 2013, compared to$147 millionin the second quarter of 2012.  The increase was principally due to increased R&D activities, primarily related to the Company's antibody collaboration with Sanofi, higher R&D headcount, and higher non-cash share-based compensation expense.  In the second quarter of 2013, R&D related non-cash share-based compensation expense was$28 million, compared to$11 millionin the second quarter of 2012.

Selling, General, and Administrative (SG&A) Expenses:GAAP SG&A expenses were$72 millionin the second quarter of 2013, compared to$48 millionin the second quarter of 2012.  The increase was primarily due to higher expenses in connection with commercialization of EYLEA and higher non-cash share-based compensation expense.  In the second quarter of 2013, SG&A related non-cash share-based compensation expense was$16 million, compared to$8 millionin the second quarter of 2012.

Cost of Goods Sold (COGS):GAAP COGS was$27 millionin the second quarter of 2013, compared to$22 millionin the second quarter of 2012.  The increase was due to higher EYLEA sales in 2013.

Cost of Collaboration Manufacturing:GAAP cost of collaboration manufacturing, which was$12 millionin the second quarter of 2013, primarily consisted of third party royalties, as well as costs in connection with producing commercial supplies of EYLEA for Bayer HealthCare and ZALTRAP for Sanofi.

Interest Expense:GAAP interest expense was$11 millionin both the second quarter of 2013 and 2012, which included$7 millionrelated to the Company's convertible senior notes, which were issued in October 2011.  Non-cash interest expense related to the convertible senior notes was$6 millionin the second quarter of 2013 and$5 millionin the second quarter of 2012.

In the second quarter of 2012, the Company did not recognize any income tax provision because it continued to recognize a full valuation allowance against its net operating loss carry-forward and other deferred tax assets.  In the fourth quarter of 2012, the Company recorded an income tax benefit attributable to the release of substantially all of the valuation allowance against the Company's deferred tax assets.   Starting in 2013, the Company has recorded income taxes on GAAP income using an estimated effective tax rate.  Non-GAAP net income excludes non-cash income tax expense.  The Company does not currently pay, or expect to pay in the near future, significant cash income taxes.

Non-GAAP and GAAP Net Income:The Company reported non-GAAP net income of$198 million, or$2.02per basic share and$1.73per diluted share, in the second quarter of 2013, compared to non-GAAP net income of$102 million, or$1.07per basic share and$0.90per diluted share, in the second quarter of 2012.  Non-GAAP net income excludes non-cash share-based compensation expense, non-cash interest expense related to the convertible senior notes, and non-cash income tax expense.

The Company reported GAAP net income of$87 million, or$0.89per basic share and$0.79per diluted share, in the second quarter of 2013, compared to GAAP net income of$77 million, or$0.81per basic share and$0.70per diluted share, in the second quarter of 2012.

Cash Position:AtJune 30, 2013, cash and marketable securities totaled$711 million, compared to$588 million(including$8 millionof restricted cash and marketable securities) atDecember 31, 2012.  In addition, accounts receivable related to sales of EYLEA totaled$766 millionatJune 30, 2013, compared to$592 millionatDecember 31, 2012.

Use of Non-GAAP Financial Measures:The Company believes that the presentation of non-GAAP measures is useful to investors because it excludes (i) non-cash share-based compensation expense which fluctuates from period to period based on factors that are not within the Company's control, such as the Company's stock price on the dates share-based grants are issued, (ii) non-cash interest expense related to the Company's convertible senior notes since this is not deemed useful in evaluating the Company's operating performance, and (iii) non-cash income tax expense, since the Company does not currently pay, or expect to pay in the near future, significant cash income taxes due primarily to the utilization of net operating loss and tax credit carry-forwards; therefore, non-cash income tax expense is not deemed useful in evaluating the Company's operating performance.  Furthermore, management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis.  However, there are limitations in the use of these non-GAAP financial measures as they exclude certain expenses that are recurring in nature.  Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies.  The non-GAAP financial measures should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP.  A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release.

Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2013 financial and operating results onTuesday, August 6, 2013, at8:30 AM.  To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International).  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website atwww.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

Regeneron is a leading science-based biopharmaceutical company based inTarrytown, New Yorkthat discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.  For additional information about the company, please visitwww.regeneron.com.

This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future financial performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation EYLEA®(aflibercept); unforeseen safety issues resulting from the administration of products and product candidates in patients; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or terminated without any further product success; and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year endedDecember 31, 2012.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise, unless required by law.

This news release and/or the financial results attached to this news release include amounts that are considered"non-GAAP financial measures"under SEC rules.  As required, Regeneron has provided reconciliations of these measures.

Assets:

Cash, restricted cash, and marketable securities

$

710,834

$

587,511

Accounts receivable - trade, net

767,865

593,207

Accounts receivable from Sanofi

108,151

99,913

Deferred tax assets

247,634

340,156

Property, plant, and equipment, net

419,651

379,940

Other assets

124,124

79,763

Total assets

$

2,378,259

$

2,080,490

Liabilities and stockholders' equity:

Accounts payable, accrued expenses, and other liabilities

$

164,026

$

118,604

Deferred revenue

247,594

259,173

Facility lease obligations

165,186

160,810

Convertible senior notes

308,116

296,518

Stockholders' equity

1,493,337

1,245,385

Total liabilities and stockholders' equity

$

2,378,259

$

2,080,490

TABLE 2

Revenue:

Net product sales

$     333,893

$     199,519

$     652,633

$     327,450

Sanofi collaborationrevenue

85,529

88,988

184,802

173,993

Bayer HealthCarecollaborationrevenue

31,104

9,124

46,011

21,607

Technology licensing

5,893

5,893

11,786

11,786

Other revenue

1,223

875

2,074

1,352

457,642

304,399

897,306

536,188

Expenses:

Research and development

187,463

147,373

367,762

286,235

Selling, general, andadministrative

72,463

47,705

149,723

106,133

Cost of goods sold

27,283

21,843

55,304

34,141

Cost of collaborationmanufacturing

12,330

13,364

299,539

216,921

586,153

426,509

Income from operations

158,103

87,478

311,153

109,679

Other income (expenses):

Investment income

954

501

1,410

1,111

Interest expense

(11,365)

(11,236)

(23,040)

(22,396)

(10,411)

(10,735)

(21,630)

(21,285)

Income before income taxes

147,692

76,743

289,523

88,394

Income tax expense

(60,316)

(103,273)

Net income

$       87,376

$       76,743

$     186,250

$       88,394

Net income per share - basic

$           0.89

$           0.81

$           1.91

$           0.94

Net income per share - diluted

$           0.79

$           0.70

$           1.69

$           0.81

Weighted average sharesoutstanding - basic

97,700

94,589

97,289

94,017

Weighted average sharesoutstanding - diluted

111,060

110,167

110,305

108,998

TABLE 3

GAAP net income

$    87,376

$   76,743

$   186,250

$    88,394

Adjustments:

R&D: Non-cash share-based compensation expense

27,722

11,442

54,484

21,998

SG&A: Non-cash share-based compensation expenses

16,344

7,790

42,130

20,368

COGS: Non-cash share-based compensation expense

376

391

859

502

Interest expense: Non-cash interest related to convertible

senior notes

5,535

5,316

11,316

10,534

Income taxes: Non-cash income tax expense

60,316

103,273

Non-GAAP net income

$   197,669

$ 101,682

$   398,312

$  141,796

Non-GAAP net income per share - basic

$         2.02

$      1.07

$         4.09

$        1.51

Non-GAAP net income per share - diluted(1)

$         1.73

$      0.90

$         3.50

$        1.28

Shares used in calculating:

Non-GAAP net income per share - basic

97,700

94,589

97,289

94,017

Non-GAAP net income per share - diluted(2)

115,261

114,928

114,711

113,760

(1)

For diluted non-GAAP per share calculations, excludes $1.8 million of interest expense for both the three month periods

ended June 30, 2013 and 2012, and $3.7 million of interest expense for both the six month periods ended June 30, 2013

and 2012, related to the contractual coupon interest rate on the Company's 1.875% convertible senior notes, since these

securities were dilutive

(2)

Weighted average shares outstanding includes the dilutive effect, if any, of employee stock options, restricted stock

awards, convertible senior notes, and warrants